Septerna (SEPN) Cash from Investing Activities (2023 - 2026)

Septerna's (SEPN) quarterly Cash from Investing Activities came in at -$23.8 million in Q1 2026, down 388.65% year-on-year from $8.3 million in Q1 2025, and up 87.15% quarter-over-quarter from -$185.3 million in Q4 2025.

Septerna (SEPN) Cash from Investing Activities (2023 - 2026) Analysis & Trends

Septerna's Cash from Investing Activities history runs 4 years deep, the most recent figure standing at -$23.8 million for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 388.65% year-over-year to -$23.8 million in Q1 2026; TTM through Mar 2026 was -$248.3 million, a 41.85% decrease from a year earlier, with the FY2025 full-year figure at -$229.4 million, down 42.81% from the prior year.
  • Cash from Investing Activities advanced to -$23.8 million in Q1 2026 per SEPN's latest filing, from -$185.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $9.6 million in Q1 2024 and bottomed at -$185.3 million in Q4 2025.
  • The 4-year median for Cash from Investing Activities is -$18.0 million (2024), against an average of -$41.5 million.
  • Across the five-year window, Cash from Investing Activities sank 10653.75% in 2024 and soared 93.52% in 2025, its largest moves.
  • Year by year, Cash from Investing Activities stood at -$1.2 million in 2023, then sank by 10653.75% to -$133.2 million in 2024, then tumbled by 39.07% to -$185.3 million in 2025, then surged by 87.15% to -$23.8 million in 2026.
  • Per Business Quant, the three latest SEPN Cash from Investing Activities figures stand at -$23.8 million (Q1 2026), -$185.3 million (Q4 2025), and -$38.4 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 65,839.48 Bn 65,839.20 Bn - -
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn - -
3 Akari Therapeutics 1,015.37 Bn 1,015.37 Bn - -
4 BeOne Medicines 471.39 Bn 466.59 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 122.52 Bn 115.28 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 70.33 Bn 61.58 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.74 Bn 62.74 Bn - -
8 Argenx Se 56.10 Bn 50.91 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.52 Bn 34.51 Bn 959.66 Mn -25.54 Mn
10 Septerna 1.49 Bn 1.49 Bn - -23.82 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -23.82 Mn
Mar 31, 2026 -23.82 Mn
Dec 31, 2025 -185.30 Mn
Dec 31, 2025 -185.30 Mn
Sep 30, 2025 -38.39 Mn
Sep 30, 2025 -38.39 Mn
Jun 30, 2025 -786,000.00
Jun 30, 2025 -786,000.00
Mar 31, 2025 -4.87 Mn
Mar 31, 2025 -4.87 Mn
Dec 31, 2024 -133.24 Mn
Dec 31, 2024 -133.24 Mn
Sep 30, 2024 -24.79 Mn
Sep 30, 2024 -24.79 Mn
Jun 30, 2024 -12.13 Mn
Jun 30, 2024 -12.13 Mn
Mar 31, 2024 9.57 Mn
Mar 31, 2024 9.57 Mn
Dec 31, 2023 -1.24 Mn
Dec 31, 2023 -1.24 Mn